메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Hakka Medicine: From Millennia of Heritage to Modern Industrialization - A Health Path Connecting the World

HONG KONG, Dec. 11, 2025 -- Hakka medicine is the result of deep integration between traditional Central Plains Chinese medicine and the natural environment of southern China, carrying profound historical heritage and unique clinical value. The Seventh World Hakka Entrepreneurs Convention was held in Meizhou, Guangdong from November 23 to 25. With the theme of "Gather Global Hakka Entrepreneurs • Facilitate High-Quality Development", the conference upheld the principles of "openness, innovation, cooperation, and mutual benefit," and explored new opportunities for the deve
- 김갑성 기자
- 2025-12-11 08:00
리스 파마슈티컬, 스타카토 원 브레스 테크놀로지 플랫폼 및 자산 인수... 파이프라인 확장 및 UCB와 글로벌 협력 가속화

광범위한 치료 잠재력을 가진 독자적 플랫폼 기술 '스타카토 원 브레스 테크놀로지' 인수 리스 팜의 기존 제품 파이프라인과 시너지 및 상호 보완 효과 UCB와의 글로벌 파트너십 하에 '스타카토 알프라졸람'의 라이선스 제공자 및 제조사 권리 획득 홍콩 2025년 12월 11일 -- 리스 파마슈티컬 홀딩스(Lee's Pharmaceutical Holdings Limited, 이하 "리스 팜")의 100% 자회사인 델라웨어 법인 노바 뉴마(Nova Pneuma Inc., 이하 "NPI")는 오늘 알렉자 파마슈티컬스(Alexza Pharmaceuticals, Inc., 이하 "알렉자")로부터의 자산 인수를 발표했다. 이번 거래로 리스 팜과 NPI는 지적재산권, 노하우, 상표, 제품 파이프라인, 장비, 제품 및 GMP(의약품 제조 및 품질 관리 기준) 시설 접근권을 포함한 '스타카토 원 브레스 테크놀로지(Staccato(R) One Breath Technology(R), 이하 "스타카토 OBT")' 플랫폼 및 자산에 대한 완전한 소유권을 확보하게 됐다.
- 김갑성 기자
- 2025-12-11 08:00
Samsung Biologics recognized as a global leader in water security

Company receives the highest Water Security rating in two years into participation Recognized for exceptional leadership in environmental stewardship INCHEON, South Korea, Dec. 11, 2025 -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced that it has received from the Carbon Disclosure Project (CDP) an 'A' rating in Water Security. Two years into its participation in CDP assessments, Samsung Biologics has earned the top rating in Water Security, one rating higher than last year.
- 김갑성 기자
- 2025-12-11 07:30
Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration

MELBOURNE, Australia and PALO ALTO, Calif., Dec. 11, 2025 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader in radiation oncology, to develop novel clinical applications that combine Telix's theranostic products and external beam radiation therapy (EBRT). EBRT is a widely used and validated treatment suitable for most solid malignant tumors. This treatment is typically delivered by radiation oncologists who play a central role
- 김갑성 기자
- 2025-12-11 03:30
DNV RECEIVES CMS APPROVAL FOR NEW AMBULATORY SURGERY CENTERS ACCREDITATION PROGRAM

New offering builds on DNV's value-driven approach to healthcare accreditation, focusing on continuous improvement, patient safety and public health outcomes HOUSTON, Dec. 10, 2025 -- DNV is expanding its highly regarded healthcare accreditation service to the fast-growing ambulatory surgery center (ASC) sector. The new NIAHO® ASC Accreditation Program today received official approval from the US Centers for Medicare and Medicaid Services (CMS). Ambulatory surgery centers, also known as outpatient or day surgery clinics, are among the fastest-growing seg
- 김갑성 기자
- 2025-12-10 22:32
DNV LAUNCHES ACCREDITATION FOR AMBULATORY SURGERY CENTERS

New offering builds on DNV's value-driven approach to healthcare accreditation, focusing on continuous improvement, patient safety and public health outcomes HOUSTON, Dec. 10, 2025 -- DNV is expanding its highly regarded healthcare accreditation service to the fast-growing ambulatory surgery center (ASC) sector. Ambulatory surgery centers, also known as outpatient or day surgery clinics, are among the fastest-growing segments in global healthcare. They offer a wide range of outpatient procedures and help reduce the burden on hospital systems by managing rou
- 김갑성 기자
- 2025-12-10 22:16
Lynk Pharmaceuticals and Formation Bio Enter Exclusive Development and Licensing Agreement for LNK01006

HANGZHOU, China and SHANGHAI and BOSTON, Dec. 10, 2025 -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals") and Formation Bio today announced Formation Bio's acquisition of worldwide rights, excluding Greater China, to LNK01006, a next generation central nervous system (CNS)–penetrant highly selective TYK2 inhibitor. The asset will be developed within Formation Bio's newly formed subsidiary Bleecker Bio. LNK01006 recently received IND clearance from the FDA to initiate first-in-human studies in the US. Formation Bio plans to initiate a Phase 1
- 김갑성 기자
- 2025-12-10 22:05
Indivumed and University of Rochester Medical Center expand collaboration for patient-centric discovery of novel therapeutics

Two leading entities in cancer research pledge scientific collaboration to advance precision oncology. HAMBURG, Germany and ROCHESTER, N.Y., Dec. 10, 2025 -- Indivumed is excited to announce its partnership with the world-renowned Wilmot Cancer Institute at the University of Rochester Medical Center (URMC). Leveraging Indivumed's proven approach to standardized tissue and clinical data collection for patient-centric cancer R&D, this collaboration aims to accelerate the development of novel cancer therapeutics for patients with high medical need. An integral resource
- 김갑성 기자
- 2025-12-10 21:00
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+

[ 메디채널 김갑성 기자 ] First patient from TNBC trial demonstrated 76% tumor volume shrinkage with corresponding reductions in circulating tumor cells (CTC) and clusters Reinvigoration of immune system + turning cold tumors hot Preliminary ex-vivo data in HER2+ patients demonstrates immune reinvigoration and reductions in CTC and clusters SYDNEY, Dec. 10, 2025 -- Kazia Therapeutics Limited ("Kazia" or the "Company") (NASDAQ: KZIA) today announced new data from two presentations at the 2025 San Antonio Breast Cancer Symposium (SABCS) providing compelling mech
- 김갑성 기자
- 2025-12-10 21:00
인디부메드와 로체스터 대학교 메디컬센터, 환자 중심의 신약 치료제 발굴을 위한 협력 확대

암 연구 분야의 두 선도 기관, 정밀 종양학 발전을 위한 과학 혁력 약속 독일 함부르크 및 뉴욕 로체스터, 2025년 12월 10일 -- 인디부메드(Indivumed)가 로체스터대학교 메디컬센터(University of Rochester Medical Center)의 세계적 암 연구 기관인 윌모트 암연구소(Wilmot Cancer Institute)와의 파트너십을 발표했다. 인디부메드는 표준화된 조직 및 임상 데이터 수집에 기반한 환자 중심 암 연구•개발 방식을 활용해 의학적 수요가 높은 환자들을 위한 새로운 암 치료제 개발을 가속화하는 것을 목표로 한다. 환자 중심 암 연구개발을 위한 필수 자원 인디부메드의 혁신적 플랫폼은 정밀하게 수집 및 큐레이션 된 외과적 조직 샘플과 종합적 임상 데이터를 기반으로 환자 중심의 암 연구와 신약 개발을 주도한다. 로체스터대학교 메디컬센터는 고품질 생체 샘플과 임상 환자 데이터를 인디부메드의 엄격한 표준작업지침(SOP)에 따라 수집•처리하는 핵심 역할을 맡는다. 특히 허혈 시간을 10분 이하로 최소화해 샘플의 무결성과 품질을 확보하는 점이 큰 강점으로 평가된다.
- 김갑성 기자
- 2025-12-10 21:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-12-19_FRI

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 19일 05시 00분